{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:57:38Z","timestamp":1762102658608,"version":"3.40.5"},"reference-count":58,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T00:00:00Z","timestamp":1628380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Opioid analgesics are frequently dispensed in children despite its known risk in children with a compromised airway function. The objectives of the study were to assess the prevalence of opioid analgesic dispensing in children with current asthma and to identify patient and prescriber factors associated with the dispensing of opioid versus non\u2010opioid analgesics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Children &lt;18\u2009years of age, having current asthma and receiving an incident analgesic prescription were identified from a large Medicaid Managed Care Plan during years 2013 through 2018. Current asthma was defined as both receiving an asthma diagnosis and filling an anti\u2010asthmatic medication during the 12\u2010month period prior to the analgesic medication initiation. A scoring algorithm was applied to associate analgesic prescription with procedures and diagnoses according to perceived need for analgesia and time proximity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 9529 children meeting the inclusion criteria, 2681 (28.1%) received an opioid prescription. Opioid analgesic dispensing was most common among children who had an outpatient surgery\/procedure (29.4%), trauma (19.4%) dental procedure (18.4%), and respiratory infection (10.6%). Multivariable analysis indicated that non\u2010Hispanic Black (AOR: 0.39[0.3\u20130.5]) and Hispanic (AOR: 0.51[0.4\u20130.6]) children were less likely to receive an opioid analgesic compared to their non\u2010Hispanic White counterparts. Children with prior history of asthma\u2010related emergency department visit (AOR: 1.24[1.0\u20131.5]) and short acting beta agonist overuse (AOR: 1.33[1.1\u20131.7]) were more likely to fill an opioid analgesic prescription than those without.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Opioid analgesics are frequently dispensed to children with asthma. A higher dispensing rate was observed among non\u2010Hispanic White children and among those with a history of uncontrolled asthma.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5336","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T07:30:59Z","timestamp":1627543859000},"page":"1520-1531","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Utilization of opioid versus non\u2010opioid analgesics in Medicaid and <scp>CHIP<\/scp> enrolled children with current asthma"],"prefix":"10.1002","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0044-0423","authenticated-orcid":false,"given":"Abhishek A.","family":"Nair","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy University of Houston  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold J.","family":"Farber","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Pulmonology Baylor College of Medicine and Texas Children's Hospital  Houston Texas USA"},{"name":"Medical Affairs Texas Children's Health Plan  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7889-8023","authenticated-orcid":false,"given":"Hua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy University of Houston  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,8,8]]},"reference":[{"unstructured":"Most Recent Asthma Data Data Statistics and Surveillance Asthma. CDC.https:\/\/www.cdc.gov\/asthma\/most_recent_national_asthma_data.htm","key":"e_1_2_8_2_1"},{"unstructured":"National Center for Health Statistics. FastStats \u2010 Asthma.https:\/\/www.cdc.gov\/nchs\/fastats\/asthma.htm","key":"e_1_2_8_3_1"},{"volume-title":"Bronchial Asthma. Current Clinical Practice","year":"2006","author":"Albertson TE","key":"e_1_2_8_4_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_5_1","DOI":"10.1097\/PAF.0000000000000138"},{"doi-asserted-by":"publisher","key":"e_1_2_8_6_1","DOI":"10.2174\/138161212803582469"},{"doi-asserted-by":"publisher","key":"e_1_2_8_7_1","DOI":"10.1016\/j.pmn.2010.02.001"},{"doi-asserted-by":"publisher","key":"e_1_2_8_8_1","DOI":"10.1007\/s12016-013-8373-z"},{"doi-asserted-by":"publisher","key":"e_1_2_8_9_1","DOI":"10.1378\/chest.119.6.1913"},{"doi-asserted-by":"publisher","key":"e_1_2_8_10_1","DOI":"10.1097\/ALN.0b013e3181c38c25"},{"issue":"4","key":"e_1_2_8_11_1","first-page":"463","article-title":"Opioid antagonists","volume":"19","author":"Martin WR","year":"1967","journal-title":"Pharmacol Rev"},{"unstructured":"Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). Accessed July 12 2020 https:\/\/ginasthma.org\/gina-reports\/","key":"e_1_2_8_12_1"},{"unstructured":"Guidelines for Diagnosis and Management of Asthma. National Heart Lung and Blood Institute National Institutes of Health. Accessed August 12 2020.https:\/\/www.nhlbi.nih.gov\/health-topics\/guidelines-for-diagnosis-management-of-asthma","key":"e_1_2_8_13_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_14_1","DOI":"10.1542\/peds.2009-1907"},{"doi-asserted-by":"publisher","key":"e_1_2_8_15_1","DOI":"10.1542\/peds.104.6.e75"},{"doi-asserted-by":"publisher","key":"e_1_2_8_16_1","DOI":"10.1093\/bja\/aes447"},{"doi-asserted-by":"publisher","key":"e_1_2_8_17_1","DOI":"10.1046\/j.1442-200X.2001.01427.x"},{"doi-asserted-by":"publisher","key":"e_1_2_8_18_1","DOI":"10.1111\/j.1460-9592.2006.02182.x"},{"unstructured":"Texas Children's Health Plan. Updated 2020.http:\/\/www.texaschildrenshealthplan.org\/","key":"e_1_2_8_19_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_20_1","DOI":"10.1542\/peds.2016-4146"},{"doi-asserted-by":"publisher","key":"e_1_2_8_21_1","DOI":"10.1111\/j.1399-3038.2010.01121.x"},{"doi-asserted-by":"publisher","key":"e_1_2_8_22_1","DOI":"10.2146\/ajhp060256"},{"key":"e_1_2_8_23_1","first-page":"1","article-title":"Asthma prevalence, health care use, and mortality: United States, 2005\u20102009","volume":"32","author":"Akinbami LJ","year":"2011","journal-title":"Natl Health Stat Report"},{"doi-asserted-by":"publisher","key":"e_1_2_8_24_1","DOI":"10.18553\/jmcp.2016.22.7.848"},{"doi-asserted-by":"publisher","key":"e_1_2_8_25_1","DOI":"10.1177\/003335490512000506"},{"doi-asserted-by":"publisher","key":"e_1_2_8_26_1","DOI":"10.3109\/02770903.2011.585411"},{"doi-asserted-by":"publisher","key":"e_1_2_8_27_1","DOI":"10.2307\/2137284"},{"doi-asserted-by":"publisher","key":"e_1_2_8_28_1","DOI":"10.1097\/MLR.0b013e31817a835d"},{"doi-asserted-by":"publisher","key":"e_1_2_8_29_1","DOI":"10.1007\/s40266-012-0013-4"},{"doi-asserted-by":"publisher","key":"e_1_2_8_30_1","DOI":"10.1183\/13993003.01872-2019"},{"issue":"1","key":"e_1_2_8_31_1","first-page":"19","article-title":"Relationship between short\u2010acting beta2\u2010adrenergic agonist use and healthcare costs","volume":"17","author":"Silver HS","year":"2011","journal-title":"Am J Manag Care"},{"doi-asserted-by":"publisher","key":"e_1_2_8_32_1","DOI":"10.1164\/rccm.200801-060ST"},{"unstructured":"SAS Enterprise Guide 8.1. Version 8.1. SAS Institute Inc.; 2019. Accessed October 10 2019.https:\/\/support.sas.com\/en\/software\/enterprise-guide-support.html","key":"e_1_2_8_33_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_34_1","DOI":"10.1007\/978-1-4615-5347-2_9"},{"doi-asserted-by":"publisher","key":"e_1_2_8_35_1","DOI":"10.1097\/CCM.0b013e31826767a8"},{"doi-asserted-by":"publisher","key":"e_1_2_8_36_1","DOI":"10.3389\/fmicb.2016.00970"},{"volume-title":"FDA Drug Safety Communication: FDA Restricts Use of Prescription Codeine Pain and Cough Medicines and Tramadol Pain Medicines in Children; Recommends against Use in Breastfeeding Women","year":"2017","author":"Drug Safety and Availability","key":"e_1_2_8_37_1"},{"unstructured":"Drug Safety and Availability \u2010FDA Drug Safety Communication: FDA Requires Labeling Changes for Prescription Opioid Cough and Cold Medicines to Limit Their Use to Adults 18 Years and Older(2018).https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm590435.htm","key":"e_1_2_8_38_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_39_1","DOI":"10.1542\/peds.2020-0649"},{"doi-asserted-by":"publisher","key":"e_1_2_8_40_1","DOI":"10.1016\/j.surg.2019.04.005"},{"unstructured":"Drug Safety and Availability \u2010FDA Drug Safety Communication: Safety Review Update of Codeine Use in Children; New Boxed Warning and Contraindication on Use after Tonsillectomy and\/or Adenoidectomy(2013).http:\/\/wayback.archive\u2010it.org\/7993\/20170112031654\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm313631.htm","key":"e_1_2_8_41_1"},{"unstructured":"Drug Safety and Availability \u2010FDA Drug Safety Communication: FDA Evaluating the Potential Risks of Using Codeine Cough\u2010and\u2010Cold Medicines in Children(2015).https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm453125.htm","key":"e_1_2_8_42_1"},{"unstructured":"Drug Safety and Availability.FDA Drug Safety Communication: FDA Evaluating the Risks of Using the Pain Medicine Tramadol in Children Aged 17 and Younger(2015).https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm462991.htm","key":"e_1_2_8_43_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_44_1","DOI":"10.1001\/jamapediatrics.2015.1915"},{"doi-asserted-by":"publisher","key":"e_1_2_8_45_1","DOI":"10.2105\/AJPH.93.12.2067"},{"doi-asserted-by":"publisher","key":"e_1_2_8_46_1","DOI":"10.1186\/s12910-017-0179-8"},{"doi-asserted-by":"publisher","key":"e_1_2_8_47_1","DOI":"10.2105\/AJPH.2011.300621"},{"doi-asserted-by":"publisher","key":"e_1_2_8_48_1","DOI":"10.1046\/j.1460-9592.2003.00998.x"},{"doi-asserted-by":"publisher","key":"e_1_2_8_49_1","DOI":"10.1016\/j.ijporl.2019.06.006"},{"doi-asserted-by":"publisher","key":"e_1_2_8_50_1","DOI":"10.1016\/j.ijnurstu.2015.05.003"},{"doi-asserted-by":"publisher","key":"e_1_2_8_51_1","DOI":"10.1016\/j.ajem.2004.10.015"},{"doi-asserted-by":"publisher","key":"e_1_2_8_52_1","DOI":"10.1542\/peds.2011-3480"},{"unstructured":"Hysingla Package Insert. 2016.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/206627s004lbl.pdf","key":"e_1_2_8_53_1"},{"unstructured":"Vicodin Package Insert. 2017.https:\/\/www.rxabbvie.com\/pdf\/vicodin_apap_300mg_hydrocodone_5mg-7_5mg-10mg_PI.pdf","key":"e_1_2_8_54_1"},{"unstructured":"Ultram Package Insert. 2019. Accessed June 18 2020.http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/ULTRAM-pi.pdf","key":"e_1_2_8_55_1"},{"unstructured":"Tylenol with Codeine CIII package insert. 2019. Accessed June 18 2020.http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TYLENOL+WITH+CODEINE-pi.pdf","key":"e_1_2_8_56_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_57_1","DOI":"10.1097\/MD.0000000000005109"},{"issue":"421","key":"e_1_2_8_58_1","first-page":"84","article-title":"NSAID\u2010induced bronchospasm\u2013a common and serious problem. A report from MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority","volume":"95","author":"Sturtevant J","year":"1999","journal-title":"N Z Dent J"},{"doi-asserted-by":"publisher","key":"e_1_2_8_59_1","DOI":"10.1542\/peds.2017-2156"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5336","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5336","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T20:16:00Z","timestamp":1693340160000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,8]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/pds.5336"],"URL":"https:\/\/doi.org\/10.1002\/pds.5336","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2021,8,8]]},"assertion":[{"value":"2021-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}